Cybrexa to present data re its lead candidate
Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the upcoming...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the upcoming...
InveniAI® Corporation was featured in a Microsoft-sponsored series that showcases companies making a transformative impact in their industry with AI technology. Krishnan Nandabalan, Ph.D., President...
Alexion Pharmaceuticals and Zealand Pharma are collaborating to discover and develop novel peptide therapies for complement-mediated diseases. Peptides offer a number of advantages, including being...
Mostafa Analoui, Executive Director of Venture Development at the University of Connecticut, recently spoke to MetroHartford Alliance about what brought him to Connecticut, his role...
The Jackson Laboratory has signed a research agreement for up to $4.2 million with Sanofi to identify new targets to treat triple-negative breast cancer and...
Connecticut’s bioscience industry has seen tremendous progress in recent years, and its key players say they want to work with lawmakers and other stakeholders to...
BioCT is pleased to welcome Megan Rosengarten to the BioCT Board of Directors. Megan is a proven leader known for commercializing new insights and opportunities, resulting in...
Biohaven Pharmaceutical Holding Company has received orphan drug designation from the FDA for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase inhibitor, for the treatment of...
Yale researchers have developed a new way to efficiently engineer immune cells, an advance which enhances the ability to fend off cancer and other diseases....